Business Wire3h
FDA Approves Samsung Bioepis’ OSPOMYV™, XBRYK™ (denosumab-dssb), a Biosimilar to Prolia and Xgeva
Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for OS ...
FDA approves first rapid-acting insulin
According to the FDA, the medication quickly helps to lower mealtime blood sugar spikes to improve control of blood sugar in ...
Johnson & Johnson to resume U.S. Varipulse cases after safety review
Johnson & Johnson (JNJ) stock in focus as limited rollout of Varipulse heart device resumes after a safety review prompted by ...
Appili Therapeutics Inc.: Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2025
Received overwhelming shareholder support in favour of take-private transaction with Aditxt Advanced key pipeline programs, engaged regulatory authorities on ATI-1801 and preparing ATI-1701 for an Inv ...
Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update
Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused ...
MyChesCo on MSN14h
FDA Grants Fast Track Designation to PleoPharma’s PP-01 for Cannabis Withdrawal Syndrome
PleoPharma, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PP-01, ...